CD8A and neoplasm: The two treatments additionally increased the infiltration of natural killer (NK) cells and CD8+ cytotoxic T cells into the tumor microenvironment, suggesting that ICI in combination with lenvatinib and gefitinib may lead to a more potent clinical response (95).